Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study
(2002) British Journal of Haematology — Vol. 118, n° 1, p. 210-217 (2002)
Files
42361.pdf
Restricted Access - Adobe PDF
- 150.36 KB
Details
- Authors
- Abstract
- Death during the induction phase of chemotherapy remains a common event in patients with aggressive non-Hodgkin's lymphoma (NHL). In a series of patients with aggressive NHL homogeneously treated with intensive induction chemotherapy [ACVB (doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone) regimen], we determined the clinical and biological parameters that were predictive of early death. Early death was defined as death, for whatever reason, occurring within 100 d of randomization. Predictive factors were identified by logistic regression and an index predictive for individual risk of early death was designed. Among the 2210 patients treated with ACVB, there were 162 (7.3%) early deaths. There was no significant reduction in the rate of early death between 1987 and 1998. In a multivariate analysis, age > 60 years, Eastern Cooperative Oncology Group performance status > 1, serum lactate dehydrogenase > normal, serum albumin < 30 g/l, leucocyte counts > 10 x 10(9) /l and haemoglobin levels < 8.5 g/dl were found to be independent predictive factors for early death. An early death index was designed, enabling the evaluation of the individual risk of early death in young (range 2-31% risk of early death) and elderly patients (range 5-53%). Clinical and biological parameters available at diagnosis can help physicians identify patients with aggressive lymphoma at low or high risk of early death.
- Affiliations
Citations
Dumontet, C., Mounier, N., Munck, J. N., Bosly, A., Morschauser, F., Simon, D., Marit, G., Casasnovas, O., Reman, O., Molina, T., Reyes, F., & Coiffier, B. (2002). Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin’s lymphoma: a GELA study. British Journal of Haematology, 118(1), 210-217. https://doi.org/10.1046/j.1365-2141.2002.03565.x (Original work published 2002)